Q3 2018 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$51M+5.3% YoY

Gross Profit

$35M69.2% margin

Operating Income

$10M19.9% margin

Net Income

$5M9.8% margin

EPS (Diluted)

$0.42

QoQ Revenue Growth

+7.3%

Cash Flow

Operating Cash Flow

$8M

Free Cash Flow

$7M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$439M

Total Liabilities

$247M

Stockholders' Equity

$192M

Cash & Equivalents

$44M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$51M	$48M	+5.3%
Gross Profit	$35M	$27M	+29.6%
Operating Income	$10M	$9M	+8.4%
Net Income	$5M	$5M	+6.4%

Revenue Segments

Sales of generic pharmaceutical products

$30M57%

Sales of branded pharmaceutical products

$15M27%

Sales of contract manufactured products

$6M11%

Royalties From Licensing Agreements

$2M4%

Other revenues

$304,0001%

Product Development Services

$288,0001%

Geographic Segments

United States

$49M97%

Canada

$2M3%